Neurogene Inc (NGNE) — Who's Buying and Selling (13F, Q2 2026)

NGNE ranks #4275 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

115 institutions disclose a position in NGNE, but none treat it as a major bet — even Samsara BioCapital, LLC, its most concentrated holder, allocates just 4.4% of its own portfolio to it.

Casdin Capital, LLC has added to its NGNE position for two straight quarters, increasing it by $21.9M to reach $48.6M today.

Sterling Capital Management LLC has trimmed its NGNE position for two straight quarters, cutting it by $4.5K while still holding $7.2K.

NGNE is up 1.3% today, and institutions have been net buyers of $10.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

NGNE reported a net loss of $111.1M over the trailing twelve months.

• Not yet profitable — net loss of $111.1M over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income declined year over year, from -$84.4M to -$111.1M
• Operating cash flow was negative, using $77.2M in cash
• Current ratio of 16.56x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.09x equity — within a conventional range